Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business

Reuters

Wed, July 22, 2026 astatine 7:04 AM CDT 1 min read

July 22 (Reuters) - Repligen Corp said connected Wednesday it would bargain BioLife Solutions successful a cash-and-stock woody valued astatine ‌about $1.5 billion, to grow the drugmaking instrumentality provider's beingness successful ‌the fast-growing compartment therapy market.

The acquisition gives Repligen entree to BioLife's exertion to sphere ​cells passim the manufacturing process and the proviso chain, arsenic good arsenic its portfolio of cell-processing tools and high-margin consumables business.

Larger adjacent Danaher connected Tuesday signaled a betterment successful request for bioprocessing products, including ‌equipment and consumables utilized ⁠to manufacture biologic drugs, arsenic biotech and pharmaceutical companies ramp up spending aft a broader slowdown successful probe ⁠spending and lawsuit inventories successful caller years.

The acquisition comes a period aft German drugmaker Merck KGaA's $11.3 cardinal woody to bargain Bio-Techne, underscoring increasing ​interest successful ​companies making tools for cause ​development.

BioLife shareholders volition person $11.25 successful ‌cash and 0.1442 shares of Repligen for each share, valuing the compartment therapy tools supplier astatine $31 per stock — a premium of astir 6.2% to BioLife's past close.

The boards of some companies person unanimously approved the deal, which is expected to adjacent successful the 4th fourth ‌of 2026, pending regulatory and shareholder ​approvals.

The acquisition is expected to summation Repligen's ​earnings and make astatine ​least $20 cardinal successful savings successful the archetypal twelvemonth aft ‌closing by cutting overlapping costs ​and improving efficiency, ​the institution said.

BioLife had already been narrowing its absorption earlier the sale. In October 2025, the institution sold its evo cold-chain ​logistics portion for $25.5 ‌million, leaving it much focused connected products tied to compartment ​and cistron therapy.

(Reporting by Sahil Pandey successful Bengaluru; Editing ​by Tasim Zahid and Sahal Muhammed)